Home/Pipeline/Xadago (safinamide)

Xadago (safinamide)

Parkinson's disease

ApprovedMarketed

Key Facts

Indication

Parkinson's disease

Phase

Approved

Status

Marketed

Company

Newron Pharmaceuticals

About Newron Pharmaceuticals

Newron Pharmaceuticals is a development-stage biopharma focused on novel therapies for neurological diseases. Its primary achievement is the global approval and commercialization of Xadago® for Parkinson's disease, providing a revenue foundation. The company's strategy centers on advancing a pipeline of innovative small molecules for rare CNS disorders, leveraging strategic partnerships to maximize reach while retaining key rights. With a lean operational model, Newron aims to address significant unmet medical needs in neuroscience.

View full company profile

Therapeutic Areas

Neurology Psychiatry

Other Parkinson's disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active